TAS-115, a potent MET/VEGFR-targeted kinase inhibitor, is a new therapeutic approach for the treatment of bone metastasis of lung cancer

被引：0
|
作者：
Gomori, A. [1 ]
Sakuragi, M. [1 ]
Hashimoto, A. [1 ]
Ito, K. [1 ]
Haruma, T. [1 ]
Suzuki, T. [1 ]
Fujita, H. [1 ]
Fujioka, Y. [1 ]
Yonekura, K. [1 ]
Utsugi, T. [1 ]
机构：
[1] Taiho Pharmaceut Co Ltd, Tsukuba Res Ctr, Tsukuba, Ibaraki, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70641-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
515
引用
收藏
页码：167 / 168
页数：2
相关论文
共 9 条
  • [1] TAS-115, a potent MET/VEGFRs-targeted kinase inhibitor with high tolerability, to suppress NSCLC-driven bone disruption
    Fujita, Hidenori
    Gomori, Akira
    Sakuragi, Motomu
    Hashimoto, Akihiro
    Ito, Kenjiro
    Suzuki, Takamasa
    Fujioka, Yayoi
    Yonekura, Kazuhiko
    Aoyama, Takekazu
    Matsubara, Nobuaki
    Doi, Toshihiko
    Iwasawa, Yoshikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] TAS-115, a novel MET plus VEGFRs dual inhibitor, decreases the cytotoxic anticancer drug resistance in lung cancer
    Kunii, Eiji
    Ozasa, Hiroaki
    Oguri, Tetsuya
    Maeno, Ken
    Takakuwa, Osamu
    Uemura, Takehiro
    Akio, Niimi
    CANCER RESEARCH, 2014, 74 (19)
  • [3] The abnormal bone remodeling associated with prostate cancer bone metastasis is attenuated by TAS-115, the dual inhibitor for HGF/VEGF signaling
    Fujita, H.
    Matsumoto, C.
    Yonekura, K.
    Watanabe, K.
    Hirata, M.
    Miyaura, C.
    Utsugi, T.
    Inada, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 176 - 176
  • [4] The Novel VEGF Receptor/MET-Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
    Fujita, Hidenori
    Miyadera, Kazutaka
    Kato, Masanori
    Fujioka, Yayoi
    Ochiiwa, Hiroaki
    Huang, Jinhong
    Ito, Kimihiro
    Aoyagi, Yoshimi
    Takenaka, Toru
    Suzuki, Takamasa
    Ito, Satoko
    Hashimoto, Akihiro
    Suefuji, Takashi
    Egami, Kosuke
    Kazuno, Hideki
    Suda, Yoshimitsu
    Nishio, Kazuto
    Yonekura, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (12) : 2685 - 2696
  • [5] Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases
    Matsubara, N.
    Naito, Y.
    Sasaki, M.
    Yamamoto, N.
    Takahashi, S.
    Uemura, H.
    Doi, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] The prominent safety profile of TAS-115, a novel c-Met plus VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis
    Ochiiwa, Hiroaki
    Fujita, Hidenori
    Ito, Kimihiro
    Takenaka, Toru
    Huang, Jinhong
    Ito, Satoko
    Suzuki, Takamasa
    Egami, Kousuke
    Suefuji, Takashi
    Sato, Ayako
    Sato, Tsudoi
    Fujioka, Yayoi
    Kato, Masanori
    Aoyagi, Yoshimi
    Hashimoto, Akihiro
    Kazuno, Hideki
    Miyadera, Kazutaka
    Suda, Yoshimitsu
    Yonekura, Kazuhiko
    CANCER RESEARCH, 2011, 71
  • [7] TAS-115, a novel and highly potent VEGFR/MET inhibitor, shows prominent antitumor efficacy by restoring HGF-mediated hypoxia-resistant phenotype in clear cell sarcoma
    Fujita, Hidenori
    Yamada, Yukari
    Terasaka, Miki
    Fujioka, Yayoi
    Harada, Naomoto
    Hashimoto, Akihiro
    Miyadera, Kazutaka
    Matsuo, Kenichi
    Yonekura, Kazuhiko
    CANCER RESEARCH, 2016, 76
  • [8] The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer
    Watanabe, Kenta
    Hirata, Michiko
    Tominari, Tsukasa
    Matsumoto, Chiho
    Fujita, Hidenori
    Yonekura, Kazuhiko
    Murphy, Gillian
    Nagase, Hideaki
    Miyaura, Chisato
    Inada, Masaki
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (40) : 20891 - 20899
  • [9] A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression
    De Bondt, Charlotte
    Snoeckx, Annemiek
    Raskin, Jo
    JOURNAL OF THE BELGIAN SOCIETY OF RADIOLOGY, 2020, 104 (01):
1